Figure 2
Figure 2. TCRγ rearrangements at the diagnosis and during TKI therapy. Clonality of the lymphocytes was determined by PCR and gel analysis with the use of 12 primer pairs for the TCR γ gene rearrangements and 6 primer pairs for TCR δ gene rearrangements. After PCR amplification and heteroduplex treatment, the PCR products were separated by electrophoresis on a 5% Criterion gel. Gels were stained with EtBr and visualized with ultraviolet illumination. (A) Dasatinib-treated patient with LGL lymphocytosis showing clonal PCR products (white arrow) of the primer pair TCRγ 12 at diagnosis and during dasatinib therapy. Lane 2 indicates at diagnosis; lane 3, 6 months after start of dasatinib therapy during lymphocytosis; lane 4, pool of healthy controls showing polyclonal smear; lane 5, water control. (B) Imatinib-treated patient without lymphocytosis showing clonal PCR product (white arrow) of the primer pair TCRγ 6 at diagnosis. After 12 months of imatinib therapy, no clonal band was visible. Lane 2 indicates at diagnosis; lane 3, 12 months after start of imatinib therapy; lane 4, pool of healthy controls showing polyclonal smear; lane 5, water control. Positive findings were confirmed with sequencing. Vertical lines have been inserted to indicate a repositioned gel lane (DNA ladder).

TCRγ rearrangements at the diagnosis and during TKI therapy. Clonality of the lymphocytes was determined by PCR and gel analysis with the use of 12 primer pairs for the TCR γ gene rearrangements and 6 primer pairs for TCR δ gene rearrangements. After PCR amplification and heteroduplex treatment, the PCR products were separated by electrophoresis on a 5% Criterion gel. Gels were stained with EtBr and visualized with ultraviolet illumination. (A) Dasatinib-treated patient with LGL lymphocytosis showing clonal PCR products (white arrow) of the primer pair TCRγ 12 at diagnosis and during dasatinib therapy. Lane 2 indicates at diagnosis; lane 3, 6 months after start of dasatinib therapy during lymphocytosis; lane 4, pool of healthy controls showing polyclonal smear; lane 5, water control. (B) Imatinib-treated patient without lymphocytosis showing clonal PCR product (white arrow) of the primer pair TCRγ 6 at diagnosis. After 12 months of imatinib therapy, no clonal band was visible. Lane 2 indicates at diagnosis; lane 3, 12 months after start of imatinib therapy; lane 4, pool of healthy controls showing polyclonal smear; lane 5, water control. Positive findings were confirmed with sequencing. Vertical lines have been inserted to indicate a repositioned gel lane (DNA ladder).

Close Modal

or Create an Account

Close Modal
Close Modal